Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. Among authors: bartunkova j. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J. Podrazil M, et al. Among authors: bartunkova j. Oncotarget. 2015 Jul 20;6(20):18192-205. doi: 10.18632/oncotarget.4145. Oncotarget. 2015. PMID: 26078335 Free PMC article. Clinical Trial.
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.
Zemanova M, Cernovska M, Havel L, Bartek T, Lukesova S, Jakesova J, Vanasek J, Reiterer P, Kultan J, Andrasina I, Siskova L, Koubkova L, Skrickova J, Salajka F, Pesek M, Klepetko P, Beniak J, Fricke H, Kadlecova P, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Zemanova M, et al. Among authors: bartunkova j. Cancer Treat Res Commun. 2021;28:100427. doi: 10.1016/j.ctarc.2021.100427. Epub 2021 Jun 26. Cancer Treat Res Commun. 2021. PMID: 34284344 Free article. Clinical Trial.
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D, Pluta M, Spacek J, Bartos P, Wimberger P, Madry R, Markowska J, Streb J, Valha P, Hassan HIB, Pecen L, Galluzzi L, Fucikova J, Hrnciarova T, Hraska M, Bartunkova J, Spisek R. Cibula D, et al. Among authors: bartunkova j. Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20. Gynecol Oncol. 2021. PMID: 34294416 Free article. Clinical Trial.
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, Bartos P, Chovanec J, Valha P, Pluta M, Novotny Z, Spacek J, Melichar B, Kieszko D, Fucikova J, Hrnciarova T, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Rob L, et al. Among authors: bartunkova j. J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190. J Immunother Cancer. 2022. PMID: 34992091 Free PMC article. Clinical Trial.
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R, Fialova A, Vavrova K, Sochorova K, Rozkova D, Spisek R, Bartunkova J. Fucikova J, et al. Among authors: bartunkova j. Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25. Cancer Immunol Immunother. 2018. PMID: 28948333 Free PMC article. Clinical Trial.
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Mikyšková R, Štěpánek I, Indrová M, Bieblová J, Šímová J, Truxová I, Moserová I, Fučíková J, Bartůňková J, Špíšek R, Reiniš M. Mikyšková R, et al. Among authors: bartunkova j. Int J Oncol. 2016 Mar;48(3):953-64. doi: 10.3892/ijo.2015.3314. Epub 2015 Dec 29. Int J Oncol. 2016. PMID: 26718011 Free PMC article.
163 results